基因表达谱在早期乳腺癌指南适应症范围外使用的影响
本研究基于荷兰癌症登记中心2011至2014年诊断的临床低危和高危早期乳腺癌患者,评估基因表达谱(GEP)在指南适应症范围外的使用及其对辅助化疗(CT)的影响。结果显示GEP在临床低危和高危患者中均有使用,且与CT给药几率改变相关,但对检测结果的依从性有限。
要点
- 临床低危患者中4.8%(444/9354)接受GEP检测,GEP使用与辅助CT给药几率增加相关(OR=2.12,95%CI 1.44-3.11)。
- 临床高危患者中7.5%(1281/17071)接受GEP检测,GEP使用与辅助CT给药频率降低相关(OR=0.55,95%CI 0.48-0.63)。
- GEP结果不一致时,临床高危患者的依从性为71.7%,高于临床低危患者的52.2%。
核心结论
- GEP常在指南指示范围外使用,并显著影响辅助CT的给药,尽管对检测结果的依从性有限。
研究设计与样本
- 基于荷兰癌症登记中心的回顾性队列研究,纳入2011至2014年诊断的临床低危和高危早期乳腺癌患者,共26425例。
主要发现
- 临床低危患者中4.8%(444/9354)接受GEP检测,GEP使用与辅助CT给药几率增加相关(OR=2.12,95%CI 1.44-3.11)。
- 临床高危患者中7.5%(1281/17071)接受GEP检测,GEP使用与辅助CT给药频率降低相关(OR=0.55,95%CI 0.48-0.63)。
- GEP结果不一致时,临床高危患者的依从性为71.7%,临床低危患者为52.2%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In Dutch guidelines, gene expression profiles (GEP) are indicated in estrogen receptor positive early breast cancer patients in whom benefit of chemotherapy (CT) is uncertain based on traditional prognostic factors alone. Aim of the present study is to assess the use and impact of GEP on administration of adjuvant CT in breast cancer patients who have according to national guidelines a clear indication to either use or withhold adjuvant chemotherapy (clinical high or low risk). METHODS: Clinical low- and high-risk patients, according to Dutch breast cancer guidelines, diagnosed between 2011 and 2014 were selected from the Netherlands Cancer Registry. Influence of GEP use and GEP test result on CT administration was assessed with logistic regression. RESULTS: Overall, 26,425 patients were identified; 4.8% of patients with clinical low risk (444/9354), 7.5% of the patients with a clinical high risk (1281/17,071) received a GEP. GEP use was associated with significantly increased odds of CT administration in clinical low-risk patients (OR = 2.12 95% CI: 1.44-3.11). In clinical high-risk patients, GEP use was associated with a decreased frequency of CT administration (OR = 0.55, 95% CI: 0.48-0.63). Adherence to the GEP result was higher in clinical high-risk patients with a discordant GEP result as compared to clinical low-risk patients with a discordant GEP result: 71.7% vs. 52.2%, respectively. CONCLUSION: GEP is frequently used outside the indicated area and significantly influenced the administration of adjuvant CT, although adherence to the test result was limited.
引用
- Schreuder K, Kuijer A, Rutgers EJT, et al. Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area. Eur J Cancer. 2017. PMID: 28844015. doi:10.1016/j.ejca.2017.07.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。